Immunosuppression News and Research

RSS

Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.

New therapies increase survival rates in post-transplant liver cancer patients

A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

25 Mar 2010

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.

16 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

Belatacept drug can prevent graft rejection in kidney transplant recipients

The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.

4 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Novartis announced today that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

19 Feb 2010

Viral infection can suppress immune response to secondary bacterial infection

A new study reveals how infection with the influenza virus impacts the way that the immune system responds to subsequent infections. The research, published by Cell Press in the February 18th issue of the journal Cell Host and Microbe, provides a new understanding of the physiological and pathological consequences of the flu.

18 Feb 2010

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Athersys, Inc. and Angiotech Pharmaceuticals, Inc. announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Top line results of the trial are expected to be announced midyear, upon completion of the four-month patient follow-up visits and analysis of results.

17 Feb 2010

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months. The study, published today in the American Journal of Transplantation, provides the first findings to come from BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial).

17 Feb 2010

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

5 Feb 2010

Level of key immune cells in kidney transplant patients may predict risk of skin cancer

Measuring certain types of immune cells may predict the high risk of skin cancer after kidney transplantation, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

29 Jan 2010

The American Journal of Pathology: Highlights from February 2010 issue

A group led by Dr. Peter Lloyd Jones at the University of Dundee, Dundee, Scotland; the University of Colorado Denver, Aurora, CO; and the University of Pennsylvania, Philadelphia, PA has demonstrated that tenascin-C affects proto-oncogene function in breast cancer. Their report can be found in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

18 Jan 2010

AMA awards unique CPT code for Cylex' ImmuKnow assay

Cylex Incorporated® announced today that the American Medical Association (AMA) CPT Editorial Panel approved the creation of new CPT coding based on the uniqueness, clinical value and widespread use of ImmuKnow, and the fact that existing CPT codes insufficiently captured all steps and costs of testing.

12 Jan 2010

Innexus Biotechnology designs new psoriasis product

InNexus Biotechnology Inc. (TSX.V: IXS) (www.ixsbio.com), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab™ technology.

6 Jan 2010

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

Robarts Clinical Trials at The University of Western Ontario in London, Canada, has been awarded a 4.7 million dollar grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease.

5 Jan 2010

Breakthrough findings may lead to new treatments for Ebola hemorrhagic fever

Scientists at The Scripps Research Institute have determined the structure of a critical protein from the Ebola virus, which, though rare, is one of the deadliest viruses on the planet killing between 50 and 90 percent of those infected.

9 Dec 2009

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

In addition to data released in late November, ChemoCentryx, Inc., announced today more data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease.

8 Dec 2009

Amgen announces results from first Phase 1/2 study of Nplate

Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

Immunosuppression News and Research

Further Reading

New therapies increase survival rates in post-transplant liver cancer patients

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

Belatacept drug can prevent graft rejection in kidney transplant recipients

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Viral infection can suppress immune response to secondary bacterial infection

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Belatacept costimulation blocker can prevent rejection of new organs by the immune system

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Level of key immune cells in kidney transplant patients may predict risk of skin cancer

The American Journal of Pathology: Highlights from February 2010 issue

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

AMA awards unique CPT code for Cylex' ImmuKnow assay

Innexus Biotechnology designs new psoriasis product

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

Breakthrough findings may lead to new treatments for Ebola hemorrhagic fever

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Amgen announces results from first Phase 1/2 study of Nplate

CAM314 randomized Phase 3 clinical trial results released

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News